{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"QXACEHWTBCFNSA-SFQUDFHCSA-N","prefName":"Cannabigerol","symbol":"CBG","iupacName":"2-[(2E)-3,7-diméthylocta-2,6-dién-1-yl]-5-pentylbenzène-1,3-diol","aliases":["Cannabigérol"],"cas":"25654-31-3","pubchemCid":"5315659","chebiId":null,"smiles":"CCCCCC1=CC(=C(C(=C1)O)C/C=C(\\C)/CCC=C(C)C)O","molecularFormula":"C21H32O2","molecularWeight":316.48,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/5315659"}},"classification":{"family":"principal","familyLabel":"Fitocannabinoide mayor","origin":"natural","originLabel":"Naturel","structuralClassFr":null},"originSynthesis":{"heading":"Vía biosintética","summaryFr":"Descarboxilación del CBGA - precursor biosintético directo del THCA, del CBDA y del CBCA en la planta madura","originNote":"Planta","discovered":"1964"},"pharmacology":{"summaryFr":"Se lo llama la « célula madre » del cannabis porque su forma ácida - el CBGA - es el precursor biosintético directo del THCA, del CBDA y del CBCA a través de las tres sintasas correspondientes. En la planta madura, el CBG ya solo representa trazas; las variedades de alto rendimiento en CBG se cosechan pronto o proceden de quimiotipos seleccionados genéticamente. Su farmacología es, sin embargo, notable: Cascio & Pertwee (BJP 2010, 159:129) demuestran que el CBG es un agonista α2-adrenérgico muy potente (EC50 0,2–72,8 nM) y un antagonista 5-HT1A moderado (KB 51,9 nM) - un perfil que lo distingue netamente del CBD. Es ese agonismo α2 el que explica el efecto « claro y funcional » referido por los usuarios, pero también una señal de sedación/hipotensión a dosis elevada, documentada ya en la literatura de 2024. Baja afinidad CB1/CB2 (agonista parcial en el rango µM), antagonista TRPM8, agonista PPARγ. Ningún medicamento aprobado. Pipeline clínico: Fase 1 en la enfermedad inflamatoria crónica del intestino (NCT05129423) y en la ansiedad. Estatuto legal: no listado como estupefaciente en las 30 jurisdicciones UE+UK+CH+NO; en Suiza, el BetmVV-EDI exime explícitamente al CBG del anexo 6 (cannabinoides sintéticos).","receptorSummaryFr":"Agonista α-2 adrenérgico muy potente (EC50 0,2–72,8 nM), antagonista 5-HT1A moderado (KB 51,9 nM), antagonista TRPM8, baja afinidad CB1/CB2","binding":[{"target":"CB1","efficacy":"partial_agonist","relativeActivity":30,"reported":"agoniste partiel faible · µM range","confidence":"medium"},{"target":"CB2","efficacy":"partial_agonist","relativeActivity":35,"reported":"agoniste partiel","confidence":"medium"},{"target":"α2-adrénergique","efficacy":"full_agonist","relativeActivity":90,"reported":"EC50 0,2–72,8 nM","confidence":"medium"},{"target":"5-HT1A","efficacy":"antagonist","relativeActivity":55,"reported":"KB = 51,9 nM","confidence":"medium"},{"target":"TRPM8","efficacy":"antagonist","relativeActivity":50,"reported":"antagoniste","confidence":"medium"},{"target":"PPARγ","efficacy":"full_agonist","relativeActivity":40,"reported":"agoniste","confidence":"medium"}],"references":[{"label":"Cascio & Pertwee - BJP 2010 · α2/5-HT1A","pmid":"20002104","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/20002104/"},{"label":"Farha - antibactérien MRSA","pmid":null,"doi":"10.1021/acsinfecdis.9b00419","url":"https://doi.org/10.1021/acsinfecdis.9b00419"},{"label":"Valdeolivas - Huntington 2015","pmid":"25252936","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/25252936/"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calma","description":"Relajación del cuerpo y de la mente; menos ruido mental, sin somnolencia marcada.","intensity":60},{"key":"focus","label":"Claridad","description":"Atención sostenida y pensamiento claro; lucidez funcional, sin euforia.","intensity":85},{"key":"sleep","label":"Sueño","description":"Efecto sedante: favorece la conciliación del sueño y la continuidad del sueño profundo.","intensity":25},{"key":"appetite","label":"Apetito","description":"Estimulación del hambre y de la apreciación gustativa (efecto «munchies»).","intensity":50},{"key":"uplift","label":"High","description":"Euforia e intensidad sensorial; percepción del tiempo y del espacio modificada.","intensity":65}],"doseRanges":null,"humanDataCharacterised":true},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":false,"bannerTextFr":null,"toxicologyFr":null},"legal":{"scheduleStatus":"industrial-exempt","scheduleLabel":"Excepción del cáñamo","frScheduleStatus":null,"tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"Autorizado · reglamento (UE) 2021/2115","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Autorizado · uso adulto","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Cascio & Pertwee - BJP 2010 · α2/5-HT1A","pmid":"20002104","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/20002104/"},{"label":"Farha - antibactérien MRSA","pmid":null,"doi":"10.1021/acsinfecdis.9b00419","url":"https://doi.org/10.1021/acsinfecdis.9b00419"},{"label":"Valdeolivas - Huntington 2015","pmid":"25252936","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/25252936/"}],"meta":{"slug":"cbg","url":"https://es.phytogrammes.com/wiki/cbg","lastVerified":"2026-05-01","dataUpdatedAt":"2026-05-01","confidence":"high","dataCompletenessPct":80,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}